Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-News: Newron Pharmaceuticals beantragt bei US-Zulassungsbehörde FDA ein Type A Meeting vor Entblindung der Daten der STARS-Studie
DGAP-News: Newron Pharmaceuticals beantragt bei US-Zulassungsbehörde FDA ein Type A Meeting vor Entblindung der Daten der STARS-Studie
DGAP-News: Newron Pharmaceuticals beantragt bei US-Zulassungsbehörde FDA ein Type A Meeting vor Entblindung der Daten der STARS-Studie
eqs_de 
0 09.12.19
DGAP-News: Newron erhält zweite Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)
DGAP-News: Newron erhält zweite Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)
DGAP-News: Newron erhält zweite Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)
eqs_de 
0 25.11.19
DGAP-News: Newron Receives Second Tranche from Financing Agreement with European Investment Bank (EIB)
DGAP-News: Newron Receives Second Tranche from Financing Agreement with European Investment Bank (EIB)
DGAP-News: Newron Receives Second Tranche from Financing Agreement with European Investment Bank (EIB)
eqs_en 
0 25.11.19
DGAP-News: Newron erhält von der FDA den Rare-Pediatric-Disease-Status für Sarizotan zur Behandlung des Rett-Syndroms
DGAP-News: Newron erhält von der FDA den Rare-Pediatric-Disease-Status für Sarizotan zur Behandlung des Rett-Syndroms
DGAP-News: Newron erhält von der FDA den Rare-Pediatric-Disease-Status für Sarizotan zur Behandlung des Rett-Syndroms
eqs_de 
0 19.11.19
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
eqs_en 
0 19.11.19
EQS-News: Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
EQS-News: Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
eqs_en 
0 30.04.24
EQS-News: Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS): https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
EQS-News: Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
eqs_en 
0 08.04.24
EQS-News: Newron presents 2023 financial results and provides 2024 outlook: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron presents 2023 financial results and provides 2024 outlook
EQS-News: Newron presents 2023 financial results and provides 2024 outlook
eqs_en 
0 19.03.24
EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
eqs_en 
0 15.03.24
EQS-News:  Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million : https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News:  Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million 
EQS-News:  Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million 
eqs_en 
0 14.03.24
EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS) : https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)
EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)
eqs_en 
0 04.01.24
EQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide
EQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide
eqs_en 
0 29.12.23
EQS-News: Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
EQS-News: Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
eqs_en 
0 09.10.23
EQS-News: Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress
EQS-News: Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress
eqs_en 
0 04.10.23
EQS-News:  Newron appoints Margarita Chavez as board advisor: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News:  Newron appoints Margarita Chavez as board advisor
EQS-News:  Newron appoints Margarita Chavez as board advisor
eqs_en 
0 02.10.23
EQS-News: Newron announces H1 2023 results and provides R&D update: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron announces H1 2023 results and provides R&D update
EQS-News: Newron announces H1 2023 results and provides R&D update
eqs_en 
0 04.08.23
EQS-News: Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS): https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
EQS-News: Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
eqs_en 
0 15.05.23
EQS-News: Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS): https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
EQS-News: Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
eqs_en 
0 03.05.23
EQS-News: Newron announces Senior Management Team changes: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron announces Senior Management Team changes
EQS-News: Newron announces Senior Management Team changes
eqs_en 
0 02.05.23
EQS-News: Newron announces AGM 2023 results  : https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron announces AGM 2023 results  
EQS-News: Newron announces AGM 2023 results  
eqs_en 
0 18.04.23
EQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry
EQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry
eqs_en 
0 28.03.23
EQS-News: Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
EQS-News: Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
eqs_en 
0 20.03.23
EQS-News: Newron to present at the 31st European Congress of Psychiatry  : https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron to present at the 31st European Congress of Psychiatry  
EQS-News: Newron to present at the 31st European Congress of Psychiatry  
eqs_en 
0 17.03.23
EQS-News: Newron announces 2022 financial results and provides outlook for 2023: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron announces 2022 financial results and provides outlook for 2023
EQS-News: Newron announces 2022 financial results and provides outlook for 2023
eqs_en 
0 14.03.23
EQS-News: Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia : https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
EQS-News: Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
eqs_en 
0 16.02.23